Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA


1Queensland Institute of Medical Research, Brisbane, Australia
2Department of Obstetrics and Gynaecology, University of Sydney, Sydney, Australia
3Westmead Institute for Cancer Research, Westmead Hospital, Sydney, Australia
4Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, University Hospital Leuven, University of Leuven, Leuven, Belgium
5Vesalius Research Center, VIB, Leuven, Belgium
6Vesalius Research Center, University of Leuven, Belgium
7Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
8Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany
9Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
10Department of Gynaecology, Friedrich Schiller University, Jena, Germany
11Byelorussian Institute for Oncology and Medical Radiology, Aleksandrov NN, Minsk, Belarus
12Clinics of Radiation Oncology, Hannover Medical School, Hannover, Germany
13Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA
14Department of Obstetrics and Gynaecology, John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
15Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
16Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
17Department of Epidemiology, Biostatistics and HTA, Nijmegen Medical Centre, Radboud University, Nijmegen, The Netherlands
18Comprehensive Cancer Center, Nijmegen, The Netherlands
19Department of Gynaecology, Nijmegen Medical Centre, Radboud University, Nijmegen, The Netherlands
20Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
21Department of Gynecology, Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
22Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada
23Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
24Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada
25Division of Epidemiology and Biostatistics, University of New Mexico, Albuquerque, NM, USA
26Alberta Health Services — Cancer Care, Calgary, Alberta, Canada
27Departments of Oncology and Public Health and Primary Care, University of Cambridge, Cambridge, UK
28Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
29Gynaecological Oncology Unit, UCL EGA Institute for Women’s Health, University College London, London, UK
30The Cancer Institute of New Jersey, New Brunswick, NJ, USA
31Memorial Sloan-Kettering Cancer Center, New York, NY, USA
*These authors contributed equally.

RECEIVED 6 March 2012; ACCEPTED 19 April 2012.

ADDRESS FOR CORRESPONDENCE: Stuart Macgregor, Queensland Institute of Medical Research, Locked Bag 2000, Herston, Queensland 4029, Australia. E-mail: stuart.macgregor@qimr.edu.au
Genome-Wide Association Studies (GWAS) have been an unprecedented success in identifying common alleles with moderate to small effects associated with different diseases and phenotypes. In particular, more than 100 common, low-penetration loci of different cancers have been uncovered by GWAS (Varghese & Easton, 2010). The discovery of susceptibility loci will provide significant insights to cancer etiology and an improved understanding of the mechanisms of tumor biology. In addition, loci associated with tumor progression after treatment will offer targets for therapeutic intervention, and the risk predictions based on accumulated knowledge of cancer genetics, together with environmental risk factors, will help to identify individuals with an elevated risk of cancer (Fletcher & Houlston, 2010). Although each of the common loci identified through GWAS only account for a small proportion of risk, collectively more than 20% of familial risk of prostate cancer has been explained, and ~7%, ~6%, and ~5% of familial risk of lung, colorectal, and breast cancers, respectively, can now be explained by GWAS results (Varghese & Easton, 2010). These estimates are likely to be conservative, as the effects of causal variants are typically larger than the associations detected through tag single-nucleotide polymorphisms (SNPs); Fletcher & Houlston, 2010).

Globally, ovarian cancer is the seventh leading cause of cancer mortality among women. Despite its relatively rare incidence, it has the same pattern of familial aggregation as other major cancers. Early twin studies have shown that most of the excess familial risk of ovarian cancer is due to genetic factors rather than shared environmental factors (Lichtenstein et al., 2000). It is well established that although rare mutations in \textit{BRCA1} and \textit{BRCA2}, identified originally by linkage studies, are the most important genetic risk factors in terms of their high penetrance, they do not fully account for the excess ovarian cancer risk seen in families. To date, one large GWAS has been conducted on ovarian cancer susceptibility aiming to identify some of the remaining unexplained familial risk. This GWAS used relatively low-density Illumina 610K and 550K arrays for cases and controls, respectively Song et al., (2009), Bolton et al., (2010), Goode et al., (2010). The confirmed susceptibility loci reaching genome-wide significance level ($p < 5 \times 10^{-8}$) uncovered by this GWAS are at 9p22.2 near \textit{BRCAP1}, 19p13.11 near \textit{C19orf62} (also known as \textit{MERIT40}) (Bolton et al., 2010), 8q24, and 2q31; two other borderline significant loci at 3q25 and 17q21 were also identified (Goode et al., 2010). In addition, a candidate gene study has implicated the \textit{TERT} locus, which has been found to contain susceptibility SNPs by many other cancer GWAS (Johnatty et al., 2010). All these loci confer small risks (per-allele relative risk less than 1.3), supporting the concept of polygenic architecture underlying ovarian cancer susceptibility. As found in other cancer types, ovarian cancer also shows histological subtype variation. The associations identified so far are stronger for serous tumors than for other histological subtypes. To identify histology-specific risk loci, separate GWAS on different subtypes will be more powerful than a single GWAS, including all subtypes. However, the high cost of GWAS limits the desirability of carrying out studies with individual genotyping for the less common subtypes, such as endometrioid, mucinous, and clear cell ovarian cancers, which may not be well powered.

The GWAS genotyping on pooled DNA has proved to be a time- and cost-effective alternative to conventional GWAS, which individually genotype all the study subjects (Craig et al., 2009; Macgregor et al., 2006, 2008; Norton et al., 2004; Sham et al., 2002; Visscher & Le Hellard, 2003). In this study we conducted a pooled GWAS on serous ovarian cancer risk, followed by validation of the pooled results and genotyping SNPs of interest in an independent large dataset from the Ovarian Cancer Association Consortium.
We used the high-density Illumina 1M-Duo array containing 1.2 million SNPs for our pooled GWAS, because it has a superior coverage with 93% of common SNPs in the CEU population tagged at $r^2 \geq 0.8$. The aim of this study was two-fold: to test the hypothesis that common SNPs with moderate or low risks, which are not well tagged by the lower density arrays (Illumina 550K and 610K arrays used in the previous GWAS), also account for some of the residual ovarian cancer risk; and to determine whether the pooled GWAS can be effectively carried out on DNA quantified by spectrophotometry, as opposed to Picogreen absorption, which we have used previously.

Materials and Methods

Ethics Statement

This study was conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by the human ethics committee of Queensland Institute of Medical Research. All participants provided written informed consent.

Samples

We used samples from the Australian Ovarian Cancer Study (AOCS) for the pooled GWAS. AOCS ascertained ovarian cancer cases through the surgical treatment centers in Australia, and from the Cancer Registries of Queensland, South and Western Australia, New South Wales, and Victoria, while controls were population-based and drawn from the Commonwealth electoral roll (Burkey & Kanetsky, 2009). We selected 342 invasive serous cases and 643 controls for the pooled GWAS. All the study subjects were self-reported White with non-Hispanic origin. Age at diagnosis and interview was recorded for cases and controls, respectively. Detailed clinical information was also available for ovarian cancer patients, including primary site of tumor, stage and grade, and overall survival time. Most of the DNAs had been isolated using salt extraction (Chang et al., 2009), but a subset had been isolated with Qiagen columns, and so these DNAs were kept separate.

DNA concentration was measured before the pools were made by spectrophotometry using a Nanodrop, and the samples were adjusted through serial dilution to 48–52 ng/μL. Each DNA sample of 2 μL was combined for each pool, and the final concentration was verified by Nanodrop. The salt-extracted DNAs from 303 invasive serous cases were further divided into tertiles according to their overall survival time. We made a separate pool of 39 DNAs from unselected cases that were isolated with Qiagen columns. The controls were randomly placed in seven pools, each with a size of 90–91 samples. We then matched each of the three salt-extracted case sets with two of the control sets. The smaller Qiagen-extracted DNA pool was matched with the remaining control pool. Thus, we had four comparisons of case versus control pools, where each individual case was matched with approximately two individual controls (Table 1).

We used samples from 12 sites in the Ovarian Cancer Association Consortium (OCAC) in the replication stage (Table 2). In all, we genotyped 13,779 samples, including 6,966 non-Hispanic White controls and 4,651 non-Hispanic White invasive cases, among which 2,245 were of serous histology.

Genotyping and Quality Control

All the DNA pools were genotyped on Illumina Human 1M-Duo arrays using standard protocols. All pools were genotyped in triplicate, with the exception of one control pool, which was genotyped in quadruplicate. A number of quality control (QC) steps described elsewhere (Lu et al., 2010) were also applied here: (1) SNPs must have less than 10% negative intensity values on each pool; (2) The number of working probes for SNP on each pool must be larger than 20; (3) The sum of raw red and green intensity values must be more than 1,200; (4) Minor allele frequency (MAF) in the HapMap CEU samples is over 5%; (5) SNP is not present significant variance difference between case and control pools. A number of additional checks were also applied. (6) The differential amplification parameter of SNP must be between 1/3 and 3. ‘Differential amplification’ refers to a phenomenon that the alleles at a locus are unequally amplified; in these cases the allele frequency estimates are biased because of the imbalanced raw intensity value. However, the differential amplification cancels out to a good approximation when we assess the allele frequency difference between cases and controls. We discarded SNPs with very extreme differential amplification ($<1/3$ or $>3$). This additional check is equivalent to discarding SNPs with estimated allele frequencies that are very different from the reference samples, for example, the HapMap CEU samples used here. (7) SNPs that passed quality control for more than two pool pairs out of four were kept, because in

GWAS for Ovarian Cancer Susceptibility Using Pooled DNA

<table>
<thead>
<tr>
<th>Pool comparison</th>
<th>Case-control status</th>
<th>N</th>
<th>Mean age (±SD)</th>
<th>p-value of mean age difference between cases and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Case (good survival)</td>
<td>101</td>
<td>58.9 (8.6)</td>
<td>0.3038</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>182</td>
<td>57.7 (10.4)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Case (medium survival)</td>
<td>101</td>
<td>59.4 (10.5)</td>
<td>0.1223</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>182</td>
<td>57.3 (11.2)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Case (poor survival)</td>
<td>181</td>
<td>62.2 (9.5)</td>
<td>2.5e-4</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>181</td>
<td>57.3 (12.5)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Case (extracted by Qiagen columns)</td>
<td>39</td>
<td>60.5 (9.9)</td>
<td>0.0288</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>90</td>
<td>56.2 (10.8)</td>
<td></td>
</tr>
</tbody>
</table>

Note: *We stratified the cases in three large pools by overall survival time. A small subset of 39 case DNAs isolated by Qiagen columns was kept together in one pool.
The four sets of association results from each pool pair were assessed in the association test. Details of pooling allele frequencies between each pair of case/control pool were estimated from each pool, and then the differences of disequilibrium (LD) were calculated. For the SNPs of interest, the proxies (linkage disequilibrium (HWE) test >95%; (3) concordance p-value for the Hardy–Weinberg >0.05 in both cases and controls; (2) call rate >95%; (3) concordance >98% between duplicate pairs (at least 5% per study site). One SNP (rs12078260) failed the HWE test in controls.

Statistical Methods and Analytic Tools

In the pooled GWAS, the allele frequencies on each locus were determined from each pool, and then the differences of allele frequencies between each pair of case/control pool were assessed in the association test. Details of pooling data analysis were described elsewhere (Lu et al, 2010). The four sets of association results from each pool pair were then meta-analyzed, where the allele frequency difference between each set of case and control pools was weighted by its inverse variance (binomial variances in case and control pools plus pooling error variances; Macgregor et al., 2006, 2008). A pooling program that incorporates the steps of estimating pooled allele frequency, mean normalization, quality controls, and finally association test taking into account pool-specific errors, has been developed for the pooled GWAS. This program is available on request.

For individually genotyped data, the SNP association was assessed in a logistic regression model implemented in PLINK (Purcell et al., 2007). Assuming a log additive model of inheritance, the per-allele risk was estimated by fitting the number of rare alleles as a continuous variable. We did not adjust for age effect in individual genotyping (IG) validation to allow for a direct comparison of pooled and individual genotyped results on the same AOCs samples. However, the age-adjusted results were similar (results not presented). In the replication stage, both age and study site adjustments were made to account for age-related differences.

Results

In order to reduce heterogeneity, the majority of invasive serous cases from the AOCs included in the pooled GWAS had tumors that originated in the ovary (except for one case, whose tumor appeared to arise in fallopian tubes), and are of high stage (>92% cases with FIGO (International Federation of Gynaecology and Obstetrics) stage III or IV) and grade (>99% cases with grade 2 or 3). Since age at diagnosis for cases is a predictor of overall survival time, age differences were observed in the comparison of cases with poor survival and controls, which were younger than these cases. A nominally significant difference in mean age was also found in the comparison of cases extracted using Qiagen columns and controls (Table 1). After carrying out
GWAS for Ovarian Cancer Susceptibility Using Pooled DNA

extensive quality control, we tested association for 9,14,948 SNPs on each comparison of case-control pools (for details of pooling designs, see Samples in Materials and Methods section), and meta-analyzed the four sets of genome-wide association results using a standard weighting method in order to maximize statistical power.

We chose 20 SNPs from the pooled GWAS for individual genotyping in the same AOCS samples as a validation of pooled results. These SNPs were among the top-ranked SNPs from the pooled GWAS that had evidence of association with ovarian cancer susceptibility, but none of these reached genome-wide significance. Moreover, these were selected for being in the subset of SNPs not well tagged by Illumina 610K array, as one of our aims was to test the hypothesis that this pooled GWAS using denser SNP arrays could uncover additional risk SNPs not identified by the previous GWAS. These 20 SNPs were successfully genotyped for nearly all the AOCS samples included in the pooled GWAS (971 out of 985 pooled samples), but one SNP failed quality control. Table 3 compares the odds ratios (OR) and p-values from the pooled GWAS and IG validation results. Despite slight difference in samples, good concordance was observed in OR estimates, with all risk directions in agreement in both sets of results. For 15/19 SNPs, the putative associations found in the pooled GWAS were clearly validated in IG results. Therefore, by comparing the results from pooled genotyping and individual genotyping on the same set of samples, we showed that GWAS using pooled DNA, quantified by spectrometry, has the potential to estimate allele frequencies accurately and provide an efficient test of association.

In addition, we sought independent replication for these 19 SNPs by individually genotyping a total of 13,779 samples collected from 12 study sites in OCAC (Table 2). Among 4,651 eligible White invasive cases of non-Hispanic origin, the majority (>95%) were classified as having primary tumor in the ovary, as opposed to the fallopian tube or peritoneum. Unlike the AOCS cases included in the pooled GWAS, the OCAC cases on the whole were evenly distributed over all tumor stages and grades (~54% in high stage and ~58% in high grade). Two sets of analyses were performed according to histology: In the primary analysis we restricted to White non-Hispanic cases with the serous subtype, which allowed for direct replication of SNPs found in the stage 1 GWAS on serous ovarian cancer cases; whereas in the secondary analysis we included cases with all histological subtypes to determine whether these SNPs show association with ovarian cancer regardless of histological types. The association results adjusted for age and study site are presented in Table 4. The results showed no replication for any of the 19 SNPs in the analyses restricted to serous cases only (primary analysis), or in the analyses combining all histological subtypes (secondary analysis).

Discussion

To date, one ovarian cancer GWAS has revealed several SNPs associated with susceptibility. None of the identified loci showed large effects (OR: 0.76–1.30 depending on the histological subtype), but the study was well powered to find common alleles with moderate effects (Song et al., 2009). In contrast, our study of the pooled GWAS on serous ovarian cancer susceptibility was under-powered to detect the alleles with moderate effects because of small sample size. In our pooled GWAS, the published risk SNPs, rs3814113 at 9p22.2, rs2072590 at 2q31, and rs2665390 at

| Table 3: Comparison of Pooled GWAS and Individual Genotyping (IG) Validation Results for 19 SNPs in AOCS Samples |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| SNP ID      | Chr | Coordinate | Alleles* | Pooled GWAS OR | SE | P_pool b | IG validation OR | SE | P_IG |
| rs752599    | 2   | 153711404  | T/C     | 0.595          | 0.122 | 2.14E-05 | 0.637          | 0.153 | 3.01E-03 |
| rs107926444 | 11  | 85658476   | A/C     | 0.463          | 0.190 | 4.94E-05 | 0.886          | 0.176 | 4.89E-01 |
| rs1573110   | 10  | 9135501    | A/G     | 1.744          | 0.141 | 8.46E-05 | 2.003          | 0.162 | 1.41E-05 |
| rs17759746  | 2   | 28247797   | T/C     | 0.596          | 0.135 | 1.23E-04 | 0.649          | 0.158 | 5.73E-03 |
| rs8043748   | 16  | 11753732   | A/G     | 0.686          | 0.098 | 1.28E-04 | 0.679          | 0.097 | 6.84E-05 |
| rs17353424  | 8   | 107929457  | T/C     | 0.638          | 0.117 | 1.28E-04 | 0.856          | 0.267 | 3.02E-02 |
| rs7943735   | 12  | 117070081  | A/C     | 1.608          | 0.125 | 1.43E-04 | 1.680          | 0.128 | 4.39E-05 |
| rs10818911  | 9   | 129584025  | T/G     | 0.627          | 0.125 | 1.91E-04 | 0.656          | 0.150 | 4.65E-03 |
| rs4887515   | 15  | 85233018   | T/C     | 0.610          | 0.133 | 1.95E-04 | 0.573          | 0.165 | 6.48E-04 |
| Rs1903532   | 4   | 179644249  | T/G     | 0.648          | 0.116 | 1.98E-04 | 0.751          | 0.136 | 3.46E-02 |
| Rs11592097  | 10  | 2166806    | A/C     | 0.645          | 0.121 | 2.85E-04 | 0.609          | 0.194 | 9.90E-03 |
| Rs2798823   | 14  | 94490125   | A/G     | 0.687          | 0.108 | 4.76E-04 | 0.701          | 0.130 | 6.17E-03 |
| rs2086545   | 11  | 13164955   | C/G     | 1.450          | 0.109 | 6.55E-04 | 1.154          | 0.130 | 2.72E-01 |
| rs2399834   | 1   | 1603726260 | A/C     | 0.627          | 0.139 | 7.79E-04 | 0.623          | 0.175 | 6.28E-03 |
| rs1053495   | 11  | 71544054   | T/C     | 0.611          | 0.148 | 8.66E-04 | 0.779          | 0.188 | 3.84E-01 |
| rs1566198   | 18  | 11294931   | T/G     | 1.510          | 0.126 | 1.05E-03 | 1.373          | 0.128 | 1.27E-02 |
| rs16135     | 9   | 242924445  | A/G     | 0.576          | 0.200 | 1.16E-03 | 0.769          | 0.197 | 1.82E-01 |
| rs16899823  | 5   | 81992978   | T/G     | 0.665          | 0.133 | 2.20E-03 | 0.638          | 0.197 | 2.16E-02 |
| rs12027970  | 1   | 37537850   | A/C     | 0.685          | 0.124 | 2.31E-03 | 0.609          | 0.213 | 1.89E-02 |

Note: *The first allele was the risk allele of SNP.

bThe table was sorted by the strength of association found in pooled GWAS (P_pool).
3q25, showed similar ORs and in the same direction as reported previously (Goode et al., 2010; Song et al., 2009), but these reached nominal or borderline significance only (Table 5). The other three SNPs (rs8170 and rs2363956 at 19p13, and rs10088218 at 8q24) identified by the published GWAS (Bolton et al., 2010; Goode et al., 2010) were not significantly associated with risk in our results, and SNP rs9303542 at the 17q21 (Goode et al., 2010) was not on Illumina Human 1M-Duo array (Table 5). We found a similar OR for rs6504172, which is in high linkage disequilibrium with rs9303542 (r^2 = 0.841), but this SNP was not significantly associated with risk (p = 0.49). We therefore found no support for our hypothesis that additional common SNPs represented on the 1M-Duo arrays contribute to ovarian cancer risk, probably because of insufficient power in stage 1 of this pooled GWAS.

In the pooling design, we divided serous ovarian cancer cases into four case pools according to the overall survival time and/or the method in which the DNAs were isolated. In theory it would be possible to test for association of SNPs with survival time by comparing good, medium, and poor survival pools, but we would have even less power to detect reliable association with survival, so these results are not presented.

Although we were under-powered to locate any common SNPs with weak effects, our study had the potential to identify common SNPs with moderate to large effects on ovarian cancer risk if any. A notable example in cancer genetics is the common variant in KITLG with a per allele risk of 2.5 for testicular cancer, which was identified from an initial GWAS (Kanetsky et al., 2009). This empirical example suggests that although most loci exhibit smaller effect sizes, common SNPs with moderate to large effect do exist in cancer genetics, and therefore it is of interest to test similar hypotheses in different cancer types. GWAS genotyping on pooled DNA does not suffer from substantial power loss compared to a conventional study using individual genotyping. For example, in our pooled GWAS, assuming an additive effect risk allele with 20% frequency that confers a relative risk of 2, power was 80%...
even after scaling the original sample size by 10% in order to account for additional variance because of pooling errors (Macgregor et al., 2008), in comparison with 88% power using individual genotyping. An empirical study with examples of successful identification of the known variants, including the eye color locus at OCA2/HERC2 (15q11.2-q12), the age-related macular degeneration locus at CFH (1q32), and the locus for Pseudoxoefoliation syndrome at LOX1 (15q22) clearly showed that common alleles with large effects are not likely to be missed in the pooled GWAS (Craig et al., 2009). Therefore, our results suggest that there are probably not hitherto poorly tagged common SNPs with moderate to large effects still to be identified.

This study also demonstrates that it is not always necessary to measure DNA concentration by Picogreen absorption, prior to making DNA pools. At least for the set of DNAs we used, which were largely isolated by salt-extraction, this study demonstrated highly consistent results between pooled genotyping and individual genotyping. However, it is worth noting that we have previously found that the correlation between the concentrations measured by Nanodrop spectroscopy and Picogreen adsorption is high ($r^2 = 0.5107$) for a related set of 200 DNAs.

It should be noted that lack of replication in this study was not due to problems in the DNA pooling method. Since additional errors, such as pool construction errors and pool measurement errors, could be involved (Sham et al., 2002), we have implemented careful experiments and rigorous analysis to address this concern. Firstly, we performed careful experiments to ensure equal quantity of DNA contributed by individual samples during the formation of the pools; secondly, all the pools were genotyped at least thrice to yield better allele frequency estimates, and we applied stringent quality controls to limit the number of possible false positives; lastly, we accounted for additional variance because of pooling errors in the association tests.

We also validated pooling results using individual genotyping. Given that most of the top 20 SNPs from the pooled GWAS were validated in the same samples by individual genotyping, the lack of replication is most likely to be due to relatively small sample size in our stage 1 GWAS rather than due to problems with the pooling approach.

In order to improve power for GWAS using pooled DNA, larger sample sizes and higher density micro-arrays are required. However, to properly accommodate a large sample size, a balance between the statistical power and the accuracy of the allele frequency estimates is needed. A number of empirical studies have investigated the impact of pool size (up to 1,000 samples in the pool) on the accuracy of allele frequency estimate, and usually found no obvious relationship between the pool size and the accuracy of allele frequency estimation (Jawaid & Sham, 2009; Le Hellard et al., 2002; Macgregor, 2007). As indicated in Macgregor et al. (2007), most variation from pooled DNA genotyping is attributable to array error rather than pool construction error. Therefore, constructing large pools is not likely to yield a great loss of power. An optimal pool design for a limited research budget will be a few large pools, which are then genotyped for multiple times. One major criticism of the pooled GWAS is that there is no information on individual genotypes or linkage disequilibrium information, so it is generally impossible to impute missing genotypes, evaluate haplotypes, or fine map the regions of interest. However, given the cost advantage, more expensive SNP arrays with better coverage can be used to partially compensate for the power loss because of imperfect linkage disequilibrium between genetic markers and causal variants. Furthermore, fine mapping of loci identified by GWAS is usually performed in a stage 2 or 3 of genotyping once the loci have been confirmed in additional samples. Here we have investigated the use of dense Illumina 1M-Duo arrays in locating variants that were poorly tagged by previous arrays. We found that moderate to large effects on ovarian cancer risk are unlikely to exist among the SNPs on this array, but we are not able to make a clear statement about the possible existence of additional SNPs with small effects because of limited study power.

In summary, we have carried out the pooled GWAS on 342 invasive serous cases and 643 controls. The accuracy of estimated odds ratios was then validated by individually genotyping the same subjects that were included in the pool. We showed that pooled genotyping using DNAs quantified by Nanodrop spectroscopy, together with analytical tools for the pooled data, work well in terms of achieving accurate OR estimations and providing reasonable association signals. We therefore propose to use pooled GWAS for less common subtypes of cancer or orphan diseases where research funds are limited. In addition, we have developed an analytical tool for analyzing the pooled GWAS data, which will be available on request.

Acknowledgments
The Australian Ovarian Cancer Study (AOCS) Management Group (D. Bowtell, G. Chenevix-Trench, A. de Fazio, D. Gertig, A. Green, and P.M. Webb) gratefully acknowledges the contribution of all clinical and scientific collaborators (see http://www.aocsstudy.org/). The Australian Cancer Study Management Group (A. Green, P. Parsons, N. Hayward, P.M. Webb, and D. Whiteman) thanks all of the project staff, collaborating institutions, and study participants. NJ Ovarian Cancer Study (NJO) investigators (EV Bandera, SH Olson, I Orlov, L Rodriguez-Rodriguez) would like to thank Melony Williams-King and the staff at the New Jersey State Cancer Registry, in particular, Lisa Paddock. BE-LOC investigators would like to thank Gillian Peuteman, Thomas Van Brussel, and Dominiek Smeets for technical assistance. SEARCH investigators thank study participants, the Eastern Cancer Registration and Information Centre, the collaborating general practitioners, the SEARCH team.

TWIN RESEARCH AND HUMAN GENETICS OCTOBER 2012

GWAS for Ovarian Cancer Susceptibility Using Pooled DNA
for patient recruitment, and Caroline Baynes, Don Conroy, and Craig Luccarini for sample preparation. The German Ovarian Cancer Study (GER) thanks Ursula Eilber and Tanja Koehler for competent technical assistance. The Hannover–Jena Ovarian Cancer Study (HJO) gratefully acknowledges the contribution of our clinical collaborators Frauke Kramer, Wen Zheng, Peter Hillemanns, and Ingo Runnebaum. HAWAII investigators thank all study participants and members of research teams of all participating studies, including research nurses, research scientists, data entry personnel, and consultant gynecological oncologists. 

Grant Support: Y. Lu is partly supported by Australian National Health and Medical Research Council (NHMRC) grant 496675. S. Macgregor is supported by a Career Development Award from the NHMRC. NJO was funded by grants from the US National Cancer Institute (K07CA095666, R01CA83918, and K22CA138563) and the Cancer Institute of New Jersey. BELOCS was funded by the Nationaal Kankerplan initiatief 29. SEARCH is funded by the German Cancer Research Center. HAWAII is funded by the US National Institutes of Health (R01 CA58598, N01-PC-95001–20). UKO is funded by grants from the US National Institutes of Health (R01 CA58598, N01-CN-55424, N01-PC-67001, and N01-PC-95001–20). UKO is funded by the Cancer Research UK, the Eve Appeal, the OAK Foundation, and the UK Department of Health’s National Kankerplan initiatief 29. SEARCH is funded by a Career Development Award from the NHMRC. NJO was funded by grants from the US National Cancer Institute (K07CA095666, R01CA83918, and K22CA138563) and the Cancer Institute of New Jersey. BELOCS was funded by the German Cancer Research Center. HAWAII is funded by the US National Institutes of Health (R01 CA58598, N01-CN-55424, N01-PC-67001, and N01-PC-95001–20). UKO is funded by grants from the US National Cancer Institute (R01 CA58598, N01-CN-55424, N01-PC-67001, and N01-PC-95001–20). UKO is funded by the Cancer Research UK, the Eve Appeal, the OAK Foundation, and the UK Department of Health’s National Kankerplan initiatief 29.

References


